SymBio Pharmaceuticals (TSE:4582) Interest Expense: 円-75 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4582 SymBio Pharmaceuticals Ltd TSE:4582
36 GF Score
Price 円55.00
GF Value 円51.83
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is SymBio Pharmaceuticals Interest Expense?

SymBio Pharmaceuticals TSE:4582 36 Interest Expense is 円-75 Mil as of Jun. 2026. GuruFocus rates TSE:4582 with a GF Score™ of 36/100 and a GF Value™ of 円51.83 (Fairly Valued). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. SymBio Pharmaceuticals's interest expense for the three months ended in Jun. 2026 was 円 -18 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2026 was 円-75 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. SymBio Pharmaceuticals's Operating Income for the three months ended in Jun. 2026 was 円 -1,294 Mil. SymBio Pharmaceuticals's Interest Expense for the three months ended in Jun. 2026 was 円 0 Mil. SymBio Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SymBio Pharmaceuticals  (TSE:4582) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

SymBio Pharmaceuticals's Interest Expense for the three months ended in Jun. 2026 was 円0 Mil. Its Operating Income for the three months ended in Jun. 2026 was 円-1,294 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Jun. 2026 was 円0 Mil.

SymBio Pharmaceuticals's Interest Coverage for the quarter that ended in Jun. 2026 is calculated as

SymBio Pharmaceuticals had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

SymBio Pharmaceuticals Interest Expense Historical Data

* Premium members only.

The historical data trend for SymBio Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SymBio Pharmaceuticals Interest Expense Chart

SymBio Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -149.45

SymBio Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -51.64 -29.04 -11.57 -16.63 -17.96
TSE:4582
36GF Score
SymBio Pharmaceuticals Ltd TSE:4582
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SymBio Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of 円-75 Mil mean?
SymBio Pharmaceuticals (TSE:4582) has a Interest Expense of 円-75 Mil as of Jun. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on SymBio Pharmaceuticals and its competitors.
Is SymBio Pharmaceuticals' Interest Expense too high?
SymBio Pharmaceuticals' current Interest Expense is 円-75 Mil. Overall, SymBio Pharmaceuticals has a GF Score™ of 36/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Interest Expense compare to ZTS?
SymBio Pharmaceuticals' Interest Expense of 円-75 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on SymBio Pharmaceuticals and its competitors. SymBio Pharmaceuticals's current Interest Expense is 円-75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, SymBio Pharmaceuticals (TSE:4582) is currently considered Fairly Valued. The stock's GF Value™ is 円51.83, compared to a current price of 円55.00 — trading 6.1% above its estimated fair value. The current Interest Expense is 円-75 Mil. SymBio Pharmaceuticals' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For SymBio Pharmaceuticals (TSE:4582), the current Interest Expense is 円-75 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is SymBio Pharmaceuticals (TSE:4582) Overvalued in 2026?

Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued. The current stock price of 円55.00 is trading 6.1% above its estimated GF Value™ of 円51.83. GuruFocus considers SymBio Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSE:4582:

  • Interest Expense: 円-75 Mil
  • GF Value™: 円51.83 vs. price of 円55.00 (6.1% above fair value)
  • GF Score™: 36/100 with 5 warning signs

No single metric tells the full story. See the TSE:4582 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

SymBio Pharmaceuticals Business Description

Address 1-28 Toranomon 4-chome, 7th Floor, Toranomon Towers Office, Minato-ku, Tokyo, JPN, 105-0001
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
36GF Score

Get the complete analysis for TSE:4582

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円55.00
Price
円51.83
GF Value